Form 4: Immix Biopharma Director Jane Buchan Reports Stock Option Grant

Director Jane Buchan reports the acquisition of stock options in Immix Biopharma, Inc.

Summary

• On June 21, 2024, Jane Buchan, a director of Immix Biopharma, Inc. [IMMX], filed a Form 4.
• The report details the grant of stock options to Buchan on June 11, 2024.
• Buchan acquired options to purchase 33,000 shares of common stock at an exercise price of $2.04 per share.
• These options vest in twelve equal monthly installments, contingent upon continued service with the issuer.
• Following the reported transaction, Buchan directly owns 22,455 shares of common stock and options to purchase 33,000 shares.
• The options expire on June 11, 2034.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently indicate positive or negative sentiment, but rather reports a standard transaction.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biopharmaceutical industry, used to attract and retain talent and align management's interests with those of shareholders. This filing is a routine disclosure required by the SEC.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of twelve equal monthly installments is a fairly typical arrangement.
• Comparing the size of the grant (33,000 shares) to similar companies would require analyzing the overall compensation structure and market capitalization of Immix Biopharma.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates